Joel Dunning visits with Timothy M. Scanlan, Scanlan International President & Chief Executive Officer, and Brigid Scanlan Eiynck, Scanlan International Vice President, Surgical Instruments. In the interview, Mr. Dunning reviews the Scanlan family’s unique history, dedication to quality, and fascinating relationships over the years.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Critical Care
March 18, 2014
This study randomized severely septic patients to either 20% albumin or crystalloid for resuscitation, with a primary outcome of mortality at 28 days. During the first week the albumin pts had a higher MAP and lower net fluid balance. Total administered fluids did not differ between the groups. Morality was similar at 28 and 90 days, and the rate
March 18, 2014
This randomized trial assigned septic pts to resuscitation with a MAP goal of 80-85 mm Hg or 65-70 mm Hg. There was no difference in mortality at 30 or 90 days. Afib was more common in the high goal pts, and high goal pts with chronic hypertension required less renal replacement therapy.
March 15, 2014
This meta-analysis evaluated the 4 new oral anticoagulants and compared their efficacy and side-effects to those of warfarin using results from randomized trials of treatment of afib. Outcomes in nearly 72,000 recipients were evaluated, including stroke, embolic events, mortality, MI, and bleeding. The newer anticoagulants reduced stroke risk by 19